Monthly Archives: August 2022

Physiology

Marvel Fans Realize the One Thing That Makes Zero Sense About Smart Hulk – We Got This Covered

via Marvel Studios/Disney Plus

Mark Ruffalo returns in She-Hulk: Attorney at Law, with the just-premiered Disney Plus series bringing back Bruce Banner in his Smart Hulk form. As introduced in Avengers: Endgame, Smart Hulk not a name Bruce chose for himself is the perfection combination of brains and brawn, with Banner retaining his personality but getting the benefits of the Hulks indestructible big green body to go with it.

Thats all well and good, but fans are just starting to realize that one thing makes exactly zero sense about him. Specifically, why the heck does he need glasses? Throughout both Endgame and the pilot episode of She-Hulk, Smart Hulk is shown donning a pair of eyeglasses when he gets to work. But, as originally pointed out by user adamfish1981 on the r/MarvelStudios subreddit, this doesnt fit with everything we know about Hulks physiology.

Banners Hulk form is known to heal pretty much all wounds and infirmities. For example, back in The Avengers, Bruce recalled how he tried to kill himself but Hulk simply spit out the bullet. Obviously, his arm was badly injured thanks to his use of the Infinity Gauntlet in Endgame, but even that was finally healed in She-Hulk thanks to cousin Jennifers super-blood. Therefore Hulk should have perfect eyesight.

So why the glasses? Marvel has made no attempt to explain it yet, so were left to speculate that, actually, maybe Smart Hulk doesnt need them at all but Bruce keeps using them anyway out of habit. In his human form, if he was concentrating on his work, he would don his glasses, so hes simply carried on doing so even if its not strictly necessary.

The real reason, obviously, is because Hulk in a pair of glasses is an easy bit of visual exposition to tell the audience that were watching Smart Hulk not regular Hulk. Still, its not hard to imagine Tatiana Maslanys Jen mocking her cuz for his useless glasses in a future episode. Admit it, Bruce, you just wear them cause you think they make you look clever.

'+// ''+// '

See the rest here:
Marvel Fans Realize the One Thing That Makes Zero Sense About Smart Hulk - We Got This Covered

Physiology

Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA – StreetInsider.com

PIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients

BETHESDA, Md., Aug. 23, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, today announced that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the Company's Pediatric Investigation Plan (PIP). The development, regulatory review and regulatory approval of a PIP is a pre-requisite for application for approval of a new medicine for adult patients, such as DCVax-L.

The Company's approved PIP includes 2 clinical trials: one for newly diagnosed pediatric high grade glioma (HGG), and one for recurrent pediatric HGG. In each of the 2 pediatric trials, 24 patients will be treated with DCVax-L on the same treatment schedule as in the Company's Phase III trial in adult glioblastoma patients.

The primary endpoint for each of the 2 pediatric trials will be overall survival, determined by comparing the survival of DCVax-L treated patients to matched contemporaneous external controls. The external controls will be identified using the same methodology as was used to pre-specify the external controls in the Statistical Analysis Plan for the Company's Phase III trial in adult patients.

Under applicable UK law, when a new medicine is developed for adult patients, that medicine must also be tested for potential application to pediatric patients. The sponsor must develop an overall Plan to select the specific form or stage of the disease to be treated, to adapt the dosing and administration of the medicine for pediatric physiology, and to evaluate the safety and efficacy of the medicine in pediatric patients. Further, the Plan must include not just general focus areas, aims and approaches -- it must include the full design of the specific clinical trials to be carried out, including all aspects required for clinical trial approvals, such as the patient population, eligibility criteria, stage of disease, treatment regimen, trial design and endpoints.

The Plan developed by the sponsor must go through a series of stages of regulatory review and comment to reach a final approval by regulators. This process can typically take more than a year.

The final regulatory approval of the PIP must be obtained before a sponsor may submit a Marketing Authorization Application (MAA) for approval to commercialize the new medicine for adult patients. The approval may include a deferral allowing the pediatric clinical trials to actually be carried out after the MAA has been submitted, but the PIP approval itself must have been received before an MAA can be filed and go through compliance check.

Northwest Biotherapeutics worked with expert consultants for months to develop a PIP tailored for application of DCVax-L to pediatric cases of HGG. The Company submitted its proposed PIP to the MHRA in February 2022, and has been going through the regulatory review process since then. On August 17, the Company received final approval of the PIP from the MHRA.

The Company's approved PIP includes a deferral under which the pediatric trials are anticipated to be undertaken after an MAA application has been submitted.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." This Phase III trial has been completed and top line data was presented by a key investigator at a recent scientific meeting. The Company also plans to pursue development of DCVax-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and plans to prepare for Phase II trials as resources permit. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

View original content to download multimedia:https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-301610850.html

SOURCE Northwest Biotherapeutics

Read more from the original source:
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA - StreetInsider.com

Physiology

New research shows that women with pulmonary hypertension have chance at safe pregnancy thanks to advanced cross-specialty care at Temple University…

(Philadelphia, PA) For women with pulmonary hypertension, a condition in which blood flow from the heart to the lungs is under dangerously high pressure, pregnancy is risky. In fact, it is often life-threatening, with maternal-fetal mortality rates hovering around 30 to 50 percent.

Women with pulmonary hypertension who become pregnant require specialized care. Thanks to the Temple Heart & Vascular Institutes Pulmonary Hypertension, Right Heart Failure & CTEPH/PTE Program, that care is available and it is getting better. In a new study, researchers at Temple show that maternal-fetal mortality can be reduced to zero through a patient-tailored management effort focused on optimizing right heart function prior to delivery.

The study, published in the Journal of Cardiovascular Development and Disease, included seven pregnancies of women with pulmonary hypertension, all of which had excellent outcomes, with 100 percent survival for mothers and infants a success rate unheard of in published literature thus far.

While the medical recommendation for women with pulmonary hypertension is to avoid pregnancy, we need to be able to safely care for these patients when pregnancy occurs, said Anjali Vaidya, MD, FACC, FASE, FACP, Professor of Medicine at the Lewis Katz School of Medicine at Temple University, Co-Director of the Pulmonary Hypertension, Right Heart Failure & CTEPH Program, and lead author on the new study.

According to Dr. Vaidya, expertise for pulmonary hypertension is typically insufficient to meet the broad needs of patients. The combination of pulmonary hypertension and pregnancy presents unique medical challenges, owing to the additional stress that pregnancy and delivery place on the heart.

Pulmonary hypertension is marked by elevated pressure in the blood vessels running from the right side of the heart through the lungs to the left side of the heart, which causes right heart failure and can result in decreased blood-oxygen levels. Symptoms of shortness of breath, fatigue, dizziness, passing out, and chest pain can ultimately result in maternal and fetal death.

According to Paul Forfia, MD, Professor of Medicine at the Lewis Katz School of Medicine and Co-Director of the Pulmonary Hypertension, Right Heart Failure & CTEPH Program, pulmonary hypertension is too often considered as an automatic contraindication to pregnancy, before a thoughtful and expert assessment is undertaken. We have developed a conceptual framework for the assessment and management of pregnant women with pulmonary hypertension that allows for a physiology-based and relatively objective approach to management that most often leads to predictable and very favorable outcomes for the mother and baby, he explained.

The difference is in the multidisciplinary collaboration of colleagues which Drs. Forfia and Vaidya have created within Temple Heart and Vascular Institutes nationally accredited Pulmonary Hypertension Program, Maternal Fetal Medicine, and Obstetric Anesthesiology. The cross-specialty management program consists of individually tailored therapy for pulmonary hypertension and clinical assessment for the duration of pregnancy and postpartum, with special attention given to right heart function.

Managing patients with pulmonary hypertension who are pregnant requires a multidisciplinary approach, said Laura Hart, MD, Assistant Professor in the Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences at the Lewis Katz School of Medicine.

Our situation of having that combined expertise within Temple is unique, Dr. Hart explained. Not only do we have experts in the necessary fields, including in pulmonary hypertension, obstetric anesthesia, and maternal-fetal medicine, but we also have the ability to co-locate and bring cardiologists into the labor and delivery process. This combination of factors puts Temple in an excellent position to provide tailored care for pregnant women with pulmonary hypertension.

The Temple researchers hope that their work will inform the development of similar multidisciplinary efforts at other institutions. We want others to see this work and be inspired to improve outcomes for pregnant women with pulmonary hypertension, Dr. Vaidya said. Ultimately, patients need to be referred early to enable effective and expert clinical assessments, allowing us to safely optimize care for each individual.

Other researchers involved in the study include Dr. Estefania Oliveros, Pulmonary Hypertension, Right Heart Failure & CTEPH Program, Temple Heart and Vascular Institute, Department of Medicine at the Lewis Katz School of Medicine; Dr. Wadia Mulla, Director of Obstetrics and Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences at the Lewis Katz School of Medicine; and Dr. Diana Feinstein, Obstetric Anesthesiology, Department of Anesthesiology at the Lewis Katz School of Medicine.###

About Temple HealthTemple University Health System (Temple Health) is a $2.4 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. Temple Health includes Temple University Hospital (TUH)-Main Campus; TUH-Episcopal Campus; TUH-Jeanes Campus; TUH-Northeastern Campus; Temple University Hospital Fox Chase Cancer Center Outpatient Department; TUH-Northeastern Endoscopy Center; The Hospital of Fox Chase Cancer Center, together with The Institute for Cancer Research, an NCI-designated comprehensive cancer center; Fox Chase Cancer Center Medical Group, Inc., The Hospital of Fox Chase Cancer Centers physician practice plan; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., Temple Healths physician practice plan. Temple Health is affiliated with the Lewis Katz School of Medicine at Temple University.

Temple Health refers to the health, education and research activities carried out by the affiliates of Temple Health and by the Katz School of Medicine. Temple Health neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with Temple Health member organizations. Each Temple Health member organization is owned and operated pursuant to its governing documents.

Non-discrimination notice: It is the policy of Temple University Hospital and The Hospital of Fox Chase Cancer Center, that no one shall be excluded from or denied the benefits of or participation in the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

Journal of Cardiovascular Development and Disease

Management of Pulmonary Arterial Hypertension in Pregnancy: Experience from a Nationally Accredited Center

18-Jun-2022

Read more:
New research shows that women with pulmonary hypertension have chance at safe pregnancy thanks to advanced cross-specialty care at Temple University...

Physiology

Wisconsin school board finalizes sex education curriculum that teaches 4th graders about transgenderism – Yahoo News

A Wisconsin school board introduced new sex education for its K-12 students for the first time in a decade that includes lessons on transgenderism starting as young as the fourth grade.

The Wauwatosa School District on Monday voted in favor of its Human Growth and Development committees proposed curriculum revisions for kindergarten to high school.

As part of the recommended revision first presented on Aug. 8, the fourth-grade curriculum developed for students around 9 or 10 years of age lists a lesson on "gender identity and expression."

By the end of the lesson, the learning targets and standards say students will be able to "Have awareness of different definitions for gender, including transgender, cisgender, and non-binary;" "Understand that individuals may identify beyond male and female;" "Understand the use of pronouns around gender identity;" "Understand that a label may not describe someone perfectly;" and "Identify at least 1 trusted adult they can talk to if they have questions."

DEMOCRAT MINNESOTA AG RIPPED BY GOP CHALLENGER FOR FRIVOLOUS CLIMATE CHANGE SUIT AMID SOARING VIOLENT CRIME

The "standards alignment" says the lesson should "Explain how some people may or may not differ between biological sex at birth and gender identity." It also aims to "define cisgender, transgender, gender non-binary, gender expansive, and gender identity."

Another lesson for fourth-grade students on "sexual orientation and identity" aims to have students "Understand the difference between sexual orientation and gender identity." It also lists "characteristics of a trusted adult and identify trusted adults in the child's life."

Meanwhile, the third-grade curriculum for students even younger also has a "gender identity and expression" lesson that mainly focuses on understanding the use of different gender pronouns.

Story continues

Other aspects of the curriculum focus on consent and healthy relationships, anatomy and physiology, puberty and identifying interpersonal violence, such as sexual abuse and sexual harassment.

The committees purpose statement says, "Together with a community of educators and families, students in the WSD will be empowered to develop healthy relationships, to engage in respectful communication, and to practice responsible decision-making that is grounded in the importance of self-worth and the dignity of others. Prepared instructors will provide grade level appropriate information on sexual health that is current, factual, consistent, and inclusive."

Wauwatosa Superintendent Demond Means told WISN on Monday that up to about 13% of students in the district are identifying themselves with different sexual orientations. He argued that most of the feedback on the curriculum changes has been positive from parents, educators and students.

"What we're finding is that a lot of our students are experiencing dating violence and sexual violence," Means said Monday. "We're also recognizing a lot of our students are identifying themselves with different sexual orientations. That number is up to 13%."

During an Aug. 8 school board meeting, meanwhile, one frustrated parent said of the new curriculum, "This isn't education. It's indoctrination. It's my job as a parent to talk to my kids about this, not yours."

See original here:
Wisconsin school board finalizes sex education curriculum that teaches 4th graders about transgenderism - Yahoo News

Physiology

Meet the Winners of the 2022 DST Launch Seed Grants – Duke Today

The Office for Research & Innovation has awarded funding to eight, interdisciplinary projects as part of the inaugural Duke Science and Technology (DST) Launch Seed Grant Program. This years winners include faculty from multiple disciplines across campus and the School of Medicine who were selected out of 61 proposal finalists for initiating high-impact projects that could lead to additional external funding.

The quality of innovative ideas our faculty have for advancing collaborative research projects continues to set Duke apart, said Jenny Lodge, Dukes vice president for Research & Innovation. This years DST Launch Seed Grants winners represent the strength of our different schools and distinct disciplines scientific research Each with the potential of making significant contributions to the region and nation.

MEDICINE + ENGINEERING

PIs: Yun Wang, Assistant Professor of Psychiatry and Behavioral Sciences; Hai Helen Li, Professor of Electrical and Computer Engineering

This team aims to develop a user-friendly, cloud-based tool for analyzing MRI scans of developing infant brains. It will be based on artificial intelligence, but users will not be required to have any advanced computational skills to take advantage of the platform, named FINNEAS, the Federated Infant Neuroimaging Analysis Platform. The system will also accommodate patient privacy and differences in data from one scanning center to the next.

ENGINEERING + MEDICINE

PIs: Aaron Franklin, Addy Professor of Electrical and Computer Engineering; Jonathan Campbell, Associate Professor of Medicine; Fan Yuan, Professor of Biomedical Engineering

This team will be studying an electronic tattoo device for continuously delivering drugs to treat type two diabetes through the skin. The printed device will be tested on skin samples to demonstrate its functionality.

GLOBAL HEALTH + MEDICINE + PUBLIC POLICY + SOCIAL SCIENCES

PIs: Sara LeGrand, Associate Research Professor of Global Health; Carly E. Kelley, M.D., M.P.H., Assistant Professor of Medicine; Kathryn Whetten, Professor of Public Policy; Gabriel Rosenberg, Associate Professor of Gender, Sexuality and Feminist Studies

Expanding on an initial infrastructure built under previous funding, this multidisciplinary team is going to assess structural inequities faced by transgender and non-binary people as they seek health care, including gender-affirming care. A patient population built from Duke Health and the Mayo Clinic will be regularly assessed to answer long-term mental and physical health questions about this population and the hope is that this resource can attract further funding and expand, once it has been built.

NATURAL SCIENCES + ENGINEERING

PIs: Lucia Strader, Associate Professor of Biology; Ashutosh Chilkoti, Alan L. Kaganov Distinguished Professor of Biomedical Engineering

This team, led by a plant biologist and a biomedical engineer, is pursuing a method to engineer a key transcription factor that drives plant growth to be optimized for higher temperatures. Building on a discovery about how plants stockpile this protein to respond to environmental change, and the ability to engineer temperature-sensitive synthetic gene transcription factors, the team hopes to tune plant growth at different temperatures.

NATURAL SCIENCES + ENVIRONMENT + ENGINEERING

PIs: Emily Bernhardt, James B. Duke Distinguished Professor of Biology; Nishad Jayasundara, Assistant Professor of Environmental Toxicology and Health; Heileen Hsu-Kim, Professor of Civil and Environmental Engineering; Jonathan Behrens, University Program in Ecology Ph.D. Student

Building on preliminary work by a Bass Connections team, this project will be sampling ten different areas of the Ellerbe Creek Watershed, which drains most of Durham into Falls Lake. Rather than measuring every compound in the stream, they are looking for contaminant signals that indicate various types of human activity: Sucralose sweetener from human waste, a chemical additive found in automobile tires from road runoff, and the herbicide RoundUp and its breakdown products from landscaping. These will be used as indicators to model the mix of sources reaching the stream. Laboratory fish will be used to assess the biological effects of different mixtures.

NATURAL SCIENCES + SOCIAL SCIENCES

PIs: Hau-Tieng Wu, Associate Professor of Mathematics; Jana Schaich Borg, Associate Research Professor in the Social Science Research Institute

Using hundreds of hours of recorded video conversations, this team will use artificial intelligence to measure the growing trust and synchrony between two interacting people, as depicted by their body poses and facial expressions. They are looking for motifs of social interaction that are stereotypical and re-used in many interactions in the hope that they can begin to uncover what they call the behavioral grammar of social interactions. These tools might eventually be used to measure social interaction disorders.

ENGINEERING + MEDICINE

PIs: Jessilyn Dunn, Assistant Professor of Biomedical Engineering; Shelley Hwang, M.D., M.P.H., Mary and Deryl Hart Distinguished Professor of Surgery

This team will be using wearable devices to monitor up to 50 patients before and after surgery as a way to track surgical recovery. Inexpensive, unobtrusive monitoring of post-operative physiology may help to identify early complications after surgery and reduce costly hospital readmissions.

NATURAL SCIENCES + ENGINEERING

PIs: Jie Liu, George Barth Geller Distinguished Professor of Chemistry; Natalia Litchinitser, Professor of Electrical and Computer Engineering

The team is designing a 3D catalyst system that can use solar energy to enhance chemical reactions. Their seed grant is aimed at a proof-of-concept called 3-D solid fog, a lattice of boron nitride microtubes which can be used as catalyst support for plasmonic nanoparticle to enable more efficient use of solar light in chemical synthesis. They will be using artificial intelligence to optimize the design of the microstructured fog and then testing it in solar light powered synthesis of ammonia, which is both a valuable fertilizer and a highly efficient carrier of hydrogen, storage of which will be critical to hydrogen-fueled, carbon-neutral technologies.

To learn more about the Duke Science and Technology (DST) Launch Seed Grant winners, visit research.duke.edu/dst-launch-seed-grant-opportunity.

Read this article:
Meet the Winners of the 2022 DST Launch Seed Grants - Duke Today

Physiology

ICAR- IARI Recruitment 2022: Check Posts, Qualifications, and How to Apply Here – StudyCafe

ICAR- IARI Recruitment 2022: Check Posts, Qualifications, and How to Apply Here

ICAR- IARI Recruitment 2022: Indian Agricultural Research Institute (ICAR- IARI) has invited applications for 1 position of Junior Research Fellow and 1 position of Technical Assistant purely on a contractual basis, time-bound and non-regular nature under the project on Genetic enhancement of rust resistance through mutation in chickpea

The deadline to submit applications is 25th August 2022 and the shortlisted candidates will be intimated through E-mail to appear for the interview. The interview for eligible candidates will be held on 8th September 2022. The venue of the interview will be IARIs Regional Research Centre, Opp. UAS Campus, PB. Road Dharwad. Eligible candidates are requested to send their application in the enclosed proforma (Annexure-I) along with a declaration form (Annexure-II) and a scanned copy of the original documents through email to [emailprotected] with a copy to [emailprotected] by August 25th, 2022.

Details of the ICAR- IARI Recruitment 2022 are given below:

1. Name of Post and No. of Vacancy: Junior Research Fellow 01

Emoluments for ICAR- IARI Recruitment 2022: A Fixed Emolument of Rs. 31,000 for 1st and 2nd year will be paid to the selected candidates. From 3rd year onwards Rs. 35000 will be paid. (HRA, if applicable as per BRNS guidelines).

Qualification for ICAR- IARI Recruitment 2022:

Essential: Post Graduate in Basic Science (i.e., Biotechnology/Molecular Biology/ Plant Physiology/ Life Science) OR Post Graduate in Professional Course with specialization in Plant Pathology/Plant Breeding and Genetics/Plant Physiology/ Plant Biotechnology/ from a recognized University.

Candidates selected through National Eligibility Tests (for Junior Research Fellow) as mentioned in the DST office memorandum No. SR/S9/Z-08/2018, dated January 30, 2019.

Desirable: The candidate should have a basic understanding of plant breeding, plant physiology/plant pathology, and experience in handling field crops.

2. Name of Post and No. of Vacancy: Technical Assistant 01

Emolument: Rs. 15000 (Consolidated)

Qualifications for ICAR- IARI Recruitment 2022:

Essential: Diploma in Agriculture or Allied subjects Graduate degree in any discipline from a recognized University.

Desirable: Working experience in growing and maintaining crop plants in fields and glasshouses.

Age-Limit for ICAR- IARI Recruitment 2022: Maximum age 35 years for JRF (age relaxation of five years for SC/ST & women and three years for OBC and for Technical Assistant the age shall not be more than 50 years.

How to Apply for ICAR- IARI Recruitment 2022:

The application deadline is 25th August 2022 and the short listed candidates will be intimated through E-mail to appear the interview. The interview for eligible candidates will be held on 8th September 2022. Eligible candidates are requested to send their application in the enclosed proforma (Annexure-I) along with a declaration form (Annexure-II) and a scanned copy of the original documents through email to [emailprotected] with a copy to [emailprotected] by August 25th, 2022.

The interview for eligible candidates will be held on 8th September 2022 the details of which will be communicated to eligible candidates by email/mobile.

The venue of the interview will be IARIs Regional Research Centre, Opp. UAS Campus, PB. Road Dharwad.

The last date to apply is 25.08.2022.

To Read Official Notification Click Here.

Disclaimer: The Recruitment Information Provided above is for informational purposes only. We do not provide any Recruitment guarantee. Recruitment is to be done as per the official recruitment process of the company or organization posted the recruitment Vacancy. We dont charge any fee for providing this job information. Neither the author nor Studycafe and its affiliates accept any liabilities for any loss or damage of any kind arising out of any information in this article nor for any actions taken in reliance thereon.

Read the original here:
ICAR- IARI Recruitment 2022: Check Posts, Qualifications, and How to Apply Here - StudyCafe

Immunology

Degrees of the Future 2022: Immunology & Virology – Gizmodo

Immunology and virology respectively study the strengths and weaknesses of our bodys immune system, and some of the most dangerous threats to them: viruses. As new viral outbreaks emerge and familiar viruses mutate into new threats, its crucial to know how our bodies can adapt.

Five years ago, you may not have thought that much about your own immune system or the ancient, forgotten viruses thawing out of glaciers in rural Tibet. But were in a brave new world now, one where masking is more commonplace and concerns about how our bodies will handle new illnesses. Virologists and immunologists help protect humans from future pathogens. While many immunologists and virologists have PhDs in their field, theyre not necessarily required.

The Degrees of the Future 2022 top Immunology & Virology programs are:

How did Gizmodo determine this years honorees? Check out the methodology or return to the full Degrees of the Future 2022 list.

Read the rest here:
Degrees of the Future 2022: Immunology & Virology - Gizmodo

Immunology

expert reaction to JCVI advice on COVID-19 vaccines for the autumn booster programme – Science Media Centre

August 15, 2022

The Joint Committee on Vaccination and Immunisation (JCVI) has published its advice on which COVID-19 vaccines should be used in this years autumn booster programme.

Prof Deborah Dunn-Walters, Chair of the British Society for Immunology COVID-19 Taskforce and Professor of Immunology at the University of Surrey, said:

Over the last year, researchers have been working hard to assess how we can best protect people from COVID-19 going forwards through the use of COVID-19 booster vaccines. The results from these multiple studies have been provided to the JCVI for careful analysis to decide which vaccines should be given as a booster, when this should happen and which people should receive one.

Booster vaccines do as their name suggests they provide a boost to your immune system to increase the levels of antibodies and T cells that you have to protect you against falling seriously ill with COVID-19. Previous research shows that individuals who are older or who have a weakened immune system are particularly at risk of becoming very ill if they contract COVID-19, but that vaccination does provide significant protection to them. Therefore, it is good to see these individuals, and the people they come into regular contact with, prioritised in this booster programme.

In line with previous years, we expect to see levels of circulating SARS-CoV-2 increase during the winter months. Vaccination is still the safest and most effective way to protect yourself from becoming very ill with COVID-19. Once available, it is important to take up the offer of a COVID-19 booster vaccine if you are offered it.

Prof Beate Kampmann, Professor of Paediatric Infection & Immunity and Director of the Vaccine Centre, LSHTM, said:

Availability of a bi-valent vaccine is good news but how much of a difference it would actually make remains to be seen. The currently discussed bi-valent vaccines were developed with Omicron variant BA.1 antigens in mind, and will only deliver very partial protection against BA.4 and 5. How much difference such bi-valent vaccine can actually make remains to be seen and the bi-valent vaccines have not yet been widely tested in large heterogeneous population groups. In essence, I think it is wise not to recommend a personalized vaccination approach but to go with the wider entirely pragmatic public health message that boosters are an important intervention for the winter period and should be taken up across age groups, as recommended, with the most vulnerable to be first in line.

https://www.gov.uk/government/news/jcvi-publishes-advice-on-covid-19-vaccines-for-autumn-booster-programme

All our previous output on this subject can be seen at this weblink:

http://www.sciencemediacentre.org/tag/covid-19

Declared interests

Prof Deborah Dunn-Walters: No conflict of interests to declare.

Prof Beate Kampmann: No declarations of interest.

See the article here:
expert reaction to JCVI advice on COVID-19 vaccines for the autumn booster programme - Science Media Centre

Immunology

CDI Laboratory Identifies Critical Regulators Controlling T-Cell Homeostasis Which Could Improve Cancer Therapies, Vaccines of the Future – Hackensack…

To see the Xue Lab's findings in action, watch this animation here.

A new publication in a major journal by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) could hold the key to better modulating the human immune system to fight cancer and produce vaccines of the future.

The laboratory of Hai-Hui Howard Xue at the CDI published the findings of the complex and cascading molecular interactions modulating T-cell immunology in the August issue of the journal Nature Immunology.

This is our second Nature Immunology paper from the CDI this year. The initial observation was made eight years ago, and Drs. Qiang Shan (the first author) and Weiqun Peng (our collaborators at the George Washington University) have continuously pursued mechanistic insights since then, said Xue, Ph.D., a member of the CDI.

It seeks to understand how T cell homeostasis is regulated beyond the known classical pathways, added Xue. The findings indicate that T cells can be induced to cycling while maintaining their naive status. This could change the way we harness the power of T cells heading forward.

The Xue lab in the two successive Nature Immunology publications has focused on a key dynamic of T-cell immunology: the Tcf1 transcription factor and its far-reaching molecular complexity.

Tcf1 is crucial to the immune systems memory in recognizing threats it has already faced before.

The Tcf1 transcription factor essentially preprograms a particular type of memory CD8+ T cells, called T central memory (Tcm) cells, prepping them to respond quickly and robustly to known threats, i.e., pathogens that the immune system has seen before, according to the paper earlier this year in the same journal.

That first paper pointed toward a way to improve the memory of these cells meaning potentially improving vaccines and boosting immune responses in future encounters with the same pathogens.

The new paper brings the results a step further in complexity. The scientists found that Tcf1 and Lef1 (an homologue of Tcf1) are critical in recruiting the CCCTC-binding factor (known as CTCF), a well-characterized architectural protein and a versatile transcription regulator, to key parts of the genome of the CD8+ T-cells. By so doing, Tcf1 fosters key chromatin interactions - and associated crucial gene expression programs of the CD8+ T-cells.

Xue and colleagues proved how central the Tcf1 was by knocking out the transcription factors in animal models. In so doing, it compromised the ability of CD8+ T cells to respond to two key interleukin cytokines that drive cell cycle progression to maintain a steady pool size and sustain immune competence.

By perfoming genome-wide analyses in the T cells, the scientists found significant overlap in both the Tcf1 and the CTCF binding on the CD8+ genome, thereby further demonstrating their cooperativity in multiple cellular processes.

Ultimately, they found that Tcf1 and Lef1, in working with the CTCF, provide constant supervision of this genomic architecture and confer flexibility. Together, they translate cytokine-derived signals into protein synthesis and DNA replication that underlie homeostatic proliferation of CD8+ T cells.

The prevalent overlap between Tcf1 and CTCF is unusual, and most importantly, the access of CTCF to the CD8 T-cell genome depends on Tcf1 at critical locations, said Xue. Also important to the biology side of things: both factors controlled the same set of genes regulating homeostatic proliferation.

This signifies Tcf1 and CTCF as important targets to modulate so as to amplify T cells in their nave state, which will have real implications in where science goes to harness the power of T cells in cellular therapy, Xue added.

This work has great promise, and we are thrilled to support the trailblazing work of the Xue Lab and others into new horizons of T-cell immunology, said David Perlin, Ph.D., chief scientific officer and senior vice president of the CDI.

See the article here:
CDI Laboratory Identifies Critical Regulators Controlling T-Cell Homeostasis Which Could Improve Cancer Therapies, Vaccines of the Future - Hackensack...

Immunology

Gould Fellowship in Cancer Immunology job with UNIVERSITY OF SOUTHAMPTON | 304380 – Times Higher Education

Cancer Sciences

Location: Southampton General HospitalSalary: 40,931 to 51,805Full Time Fixed TermClosing Date: Tuesday 06 September 2022Interview Date: To be confirmedReference: 1933522CM

An exciting opportunity presents itself for a new research fellowship to be established in the Centre for Cancer Immunology, within the School of Cancer Sciences at the Southampton General Hospital site. The centre, opened in 2018, builds on a 40-year history of pioneering immunology and cancer research at Southampton, and represents the first dedicated cancer immunology centre in the UK. The activities in the centre span from pioneering discovery science to applied research and pre-clinical modelling and, crucially, onto first-in-human clinical trials and beyond. The centre houses world-class research facilities, including state-of-the-art scientific laboratories and a clinical trials unit all within the same building to facilitate the most efficient translation of our findings into improved treatments for Cancer patients.

This position is associated with significant resources, up to 150k/year, to enable the appointee to develop an independent research programme. The position is expected to lead to success of the appointee in obtaining extramural funding on the pathway to independence. The appointee will be highly motivated and excited by the challenges involved in working collaboratively with the existing research groups in the centre, whilst building their own identifiable research themes. Current research programmes involve antibody engineering, immunotherapy, immune receptor biology and antigen presentation related to the treatment of cancer (www.southampton.ac.uk/youreit/meet-the-team). Ongoing activities also include mechanistic studies of therapies for autoimmunity. Research in the centre is highly interdisciplinary, and include bioinformatics, advanced microscopy and close interactions with clinicians as well as a wide group of collaborating scientists across the University (www.southampton.ac.uk/youreit/cancer-scientists)

The appointee is expected to have an outstanding research background, including high quality publications, in any area related to cancer immunology. Typically, it is expected that the appointee will have successfully completed several years of post-doctoral research, but outstanding candidates with less experience will also be considered.

The post-holder will possess relevant academic qualifications and work experience, in addition to good IT skills. Non-UK citizens are also encouraged to apply.

The position is initially fully funded for two years. Availability of funds for a third year will be dependent on satisfactory progress.

Informal queries can directed to: Professor Sally Ward (E.S.Ward@soton.ac.uk)

You should submit your completed online application form at https://jobs.soton.ac.uk. The application deadline will be midnight on the closing date sated above. If you need any assistance, please call Jane Sturgeon (Recruitment Team) on +44 (0) 23 8059 2750 or email recruitment@soton.ac.uk. Please quote reference 1933522CM on all correspondence.

Continued here:
Gould Fellowship in Cancer Immunology job with UNIVERSITY OF SOUTHAMPTON | 304380 - Times Higher Education